Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciraparantag for Reversal of Anticoagulation in Healthy Adults
NCT04593784Phase 2Terminated
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Oct 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ciraparantag in anticoagulation therapy, sponsored by AMAG Pharmaceuticals, Inc.. Started Oct 2021; status: terminated.
02
Drugs
ciraparantag
03
Conditions
anticoagulation therapy
Beyond the preview
Go deeper on NCT04593784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593784.